Image Image Image Image Image Image Image Image Image Image
Haut de page


Dr Monés joins the ophthalmological elite at the AAO’s Annual Meeting

17/10/2019 · Actualités
AAO 2019

San Francisco was the venue for the prestigious American Association of Ophthalmology’s Annual Meeting on 12-15 October. The Director of the Institut de la Màcula, Dr Jordi Monés, MD, PhD, provided advice for a number of pharmaceutical companies and biotech companies

The prestigious American Association of Ophthalmology (AAO) held its Annual Meeting in San Francisco on 12-15 October. The world’s largest ophthalmological association played host to a variety of meetings, conferences and presentations that updated knowledge and publicised latest research in the sector.

Attending the event, the Institut de la Màcula’s Director, Dr Jordi Monés, MD, PhD was invited to a variety of Advisory Boards held at the Annual Meeting. Dr Monés is a member of a number of research groups, including the Study Group of the Consensus of Atrophy (CAM); he is the Scientific Advisor of various pharmaceutical companies (Novartis, Roche, Ophthotech, Apellis, Kodiak, Genentch and Allegro), and biotech companies (CellCure and Reneuron in the field of the regenerative stem cell therapy, for Geographic Atrophy (GA) and retinitis pigmentosa respectively).

Dr Monés was invited to the meetings held on Gene Therapy, Reneuron’s hRPC Advisory Board meeting and the Advisory Board meeting: Lineage Cell Therapeutics -known previously as BioTime.

It was also announced that the Novartis pharmaceutical company has won approval from the Food and Drug Administration (FDA) of the United States for brolucizumab in injections for the treatment of age-related macular degeneration (AMD) in its exudative type. "Excellent news for patients with exudative AMD," said Dr Monés, Novartis’s Scientific Advisor, after one of the meetings of its Advisory Board.

The visual benefits sustained beyond the current short-medium term will become more possible. This drug, which is more effective and long-lasting, will reduce the unfortunate practice of undertreating patients, which is quite common. Congratulations to all who have helped to make this possible. It is a privilege and an honour to be among them,” added the Director of the Institut de la Màcula.

DMLA exsudative ou humideRétinite pigmentaire
Last modified: 29 November, 2021 - 13:07